FDA approves first generic naloxone nasal spray to treat opioid overdose
Article continues below
The agency is also planning new steps to prioritize the review of additional generic drug applications for products intended to treat opioid overdose, along with the previously announced action to help facilitate an over-the-counter naloxone product.
The approval is the first generic naloxone nasal spray for use in a community setting by individuals without medical training; however, generic injectable naloxone products have been available for years for use in a health care setting.
The FDA also has previously approved a brand-name naloxone nasal spray and an auto-injector for use by those without medical training.
While business and other considerations may impact how quickly this product becomes available, today's approval is an important step for the agency as it works toward expanding access to this live-saving drug. ■